1 / 24

PRIMA Investigator Meeting

PRIMA Investigator Meeting. Gilles Salles. Vienna, June 07. PRIMA investigator meeting. Introduction and Welcome Study & Patients Prima is a Registration trial = changes & regulatory aspects Next steps. Vienna, June 07. STATUS. From 24/12/2004 until 11/04/07 1217 patients registered

hester
Download Presentation

PRIMA Investigator Meeting

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. PRIMAInvestigator Meeting Gilles Salles Vienna, June 07

  2. PRIMA investigator meeting • Introduction and Welcome • Study & Patients • Prima is a Registration trial = changes & regulatory aspects • Next steps Vienna, June 07

  3. STATUS • From 24/12/2004 until 11/04/07 • 1217 patients registered • 25 active countries (with at least 1 patient)

  4. PRIMA : an international collaborative effort

  5. PRIMA RECRUITMENT

  6. PRIMA recruitment

  7. PRIMA RECRUITMENT Chemo regimen chosen (all pts) R-CHOP 900 74% R-CVP 272 22% R-FCM 45 4% Vienna, June 07

  8. STATUS • On June 5th, 821 patients (84% or those that reached the time of randomization) were effectively randomized: Maintenance 417 pts Observation 404 pts

  9. Randomization failure For the 146 patients (15.6%) that failed to be randomized: Major violation (inclusion criteria) 10 pts (3 Hbs +) pathology review 12 pts BM only 3 pts Major protocol violation (treatment) 11 pts 2nd cancer discovered during induction 7 pts 29% Toxicity and premature withdrawal 24 pts Delay during induction or at randomisation 20 pts 30% Treatment failure 32 pts Death 14 pts 33% Consent withdrawal 6 pts Investigator decision 4 pts 7% Vienna, June 07

  10. Patients characteristics(CRF registered, medical review ongoing) Vienna, June 07

  11. Patients characteristics(CRF registered, medical review ongoing) (only 112 patients - 10% - had those sole criteria) Vienna, June 07

  12. Patients characteristics(CRF registered, medical review ongoing) Vienna, June 07

  13. PRIMA had became a registration trial • Agreement between GELA, Roche and Genentech • The results will be used for registration filing - in EU, US and rest of the world • New responsibilities • For the sponsor (GELA) • For the investigators • For the coordinating centers • For the partners (Roche, Genentech) • For the DSMB • … Vienna, June 07

  14. To become a registration trial • New protocol version (version 4.0, amendment 3) needed some changes: • Compliance with Health Authorities (EMEA, FDA) requirements (PFS, etc…) • Update statistical hypothesis taking into account the results of the EORTC and GLSG studies (sample size) • Changes in protocol and ICF for new and already registered patients • Approval of the DSMC • August 4th 2006 • Submission to the ethics and health authorities in the lead sponsor country : August 18th 2006 • Approval by French authorities September 2006 • Dissemination of new protocol and ICF versions to other countries: • September 18th • Accrual resumed from October 9th until January in most countries Vienna, June 07

  15. Regulatory aspects • 3rd amendment approval needed even if no additional patient was included (regulatory, follow-up, etc…) • No CT scan collection without this approval • Additional ICF to be signed by patients registered before the 3rd amendment • New contract between GELA – cooperative group/Roche affiliate Vienna, June 07

  16. Monitoring and follow-up • Close monitoring of centers (every 2 months) to • complete and clean the data base - 89% of baseline received (2% incomplete) - 72% of induction / response received (11% incomplete) - 65% of first follow-up received (40% incomplete) • Assure timely follow-up of patients and events • Answer queries • CT-scan review process with Bio-Imaging (only for randomized patients) Vienna, June 07

  17. Some clinical aspects“maintenance or observation” 1) Please follow the protocol recommendations for - visits every 8 weeks during the 2 years arm A & B then - clinical visits every 3 months (2 y) and 6 months (3 y) - CT scans every 6 months (3 y) and 12 months (2 y) 2) For women in age of being pregnant: - please recommend contraceptives in the maintenance arm Vienna, June 07

  18. PRIMAsafety • No obvious safety issues reported during induction • - next DSMB meeting in 2007 • Follow carefully AE and SAE during maintenance • Document well what happens • Follow-up of patients with side effects • EORTC intergroup study data • Any clinical study has to weight the risk/benefit ratio Vienna, June 07

  19. PRIMAefficacy • Progression: 1) Fast track declaration of progressions after randomization by FAX 2) Document well : • Tumor measurements (CT scans) • Biopsy • Treatment (can be delayed) 3) Follow subsequent events : Death • Adequate follow-up for all patients • Respect planed visits and evaluation Vienna, June 07

  20. Financial agreements • Patient fees were changed • After randomization • Time of final analysis • End of study • + CT-scan review • First payments to the country coordinating group in GELA-sponsored country will be done in timely manner • June 07 (if the amended contract signed) • Then once a year • Final analysis • End of study Vienna, June 07

  21. Next steps for PRIMA • With 1217 pts recruited, PRIMA is the largest trial ever performed in first line follicular lymphoma patients • An opportunity for answering a very important question with a high standard quality trial : • Rituximab maintenance benefit after R-chemo Vienna, June 07

  22. Progression-free survivalafter R-CHOP 100 90 80 70 60 50 40 30 20 10 0 Median 51.9 months Progression-free survival (%) Median 23.1 months Overall log-rank test: p=0.004; HR: 0.54 0 1 2 3 4 5 Years O N Number of patients at risk : Treatment 55 98 59 31 13 4 34 91 65 48 27 8 MabThera Results of R-CHOP maintenance in the EORTC intergroup study Vienna, June 07

  23. Time for analysis • Estimated number of event to confirm the hypothesis (45% increase of PFS) : 344 events • First interim analysis to be performed when 172 events will have occurred • Close tracking of events – - fax progression /death pages to gelarc “on line” • Expected first semester of 2008 ? • Will be blinded and presented to the DSMC Vienna, June 07

  24. Thanks to all of you for your cooperation Vienna, June 07

More Related